Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX) and Mirum Pharmaceuticals (NASDAQ: MIRM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on RegenXBio (RGNXResearch Report) and Mirum Pharmaceuticals (MIRMResearch Report).

RegenXBio (RGNX)

RBC Capital analyst Luca Issi maintained a Hold rating on RegenXBio today and set a price target of $55.00. The company’s shares closed last Monday at $43.40.

According to TipRanks.com, Issi has 0 stars on 0-5 stars ranking scale with an average return of -8.5% and a 29.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Crispr Therapeutics AG.

RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $67.40, which is a 67.2% upside from current levels. In a report released yesterday, Leerink Partners also maintained a Hold rating on the stock with a $44.00 price target.

See today’s analyst top recommended stocks >>

Mirum Pharmaceuticals (MIRM)

In a report released today, Steven Seedhouse from Raymond James maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $51.00. The company’s shares closed last Monday at $17.93.

According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of 12.8% and a 48.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, NGM Biopharmaceuticals, and Intellia Therapeutics.

Currently, the analyst consensus on Mirum Pharmaceuticals is a Strong Buy with an average price target of $48.86, which is a 164.1% upside from current levels. In a report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $37.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.